Literature DB >> 26614024

The Prostate Health Index: Its Utility in Prostate Cancer Detection.

Abbey Lepor1, William J Catalona2, Stacy Loeb3.   

Abstract

The Prostate Health Index is a Food and Drug Administration-approved blood test combining total, free, and [-2]pro prostate-specific antigen with greater specificity than free and total prostate-specific antigen for clinically significant prostate cancer. This article reviews the evidence on the performance of the Prostate Health Index to predict prostate biopsy outcome, its incorporation into multivariable risk-assessment tools, and its ability to predict prognosis after conservative management or prostate cancer treatment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Detection; Prostate Health Index; Prostate cancer; Screening

Mesh：

Substances：

Year:  2016        PMID： 26614024      PMCID： PMC4663012          DOI： 10.1016/j.ucl.2015.08.001

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  22 in total

1.  Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.

Authors:  Giorgio Guazzoni; Massimo Lazzeri; Luciano Nava; Giovanni Lughezzani; Alessandro Larcher; Vincenzo Scattoni; Giulio Maria Gadda; Vittorio Bini; Andrea Cestari; Nicolò Maria Buffi; Massimo Freschi; Patrizio Rigatti; Francesco Montorsi
Journal:  Eur Urol       Date:  2011-11-04       Impact factor: 20.096

Review 2.  The Melbourne Consensus Statement on the early detection of prostate cancer.

Authors:  Declan G Murphy; Thomas Ahlering; William J Catalona; Helen Crowe; Jane Crowe; Noel Clarke; Matthew Cooperberg; David Gillatt; Martin Gleave; Stacy Loeb; Monique Roobol; Oliver Sartor; Tom Pickles; Addie Wootten; Patrick C Walsh; Anthony J Costello
Journal:  BJU Int       Date:  2014-02       Impact factor: 5.588

Review 3.  Overdiagnosis and overtreatment of prostate cancer.

Authors:  Stacy Loeb; Marc A Bjurlin; Joseph Nicholson; Teuvo L Tammela; David F Penson; H Ballentine Carter; Peter Carroll; Ruth Etzioni
Journal:  Eur Urol       Date:  2014-01-09       Impact factor: 20.096

4.  Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

Authors:  Giorgio Guazzoni; Luciano Nava; Massimo Lazzeri; Vincenzo Scattoni; Giovanni Lughezzani; Carmen Maccagnano; Fernanda Dorigatti; Ferruccio Ceriotti; Marina Pontillo; Vittorio Bini; Massimo Freschi; Francesco Montorsi; Patrizio Rigatti
Journal:  Eur Urol       Date:  2011-04-05       Impact factor: 20.096

5.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Authors:  William J Catalona; Alan W Partin; Martin G Sanda; John T Wei; George G Klee; Chris H Bangma; Kevin M Slawin; Leonard S Marks; Stacy Loeb; Dennis L Broyles; Sanghyuk S Shin; Amabelle B Cruz; Daniel W Chan; Lori J Sokoll; William L Roberts; Ron H N van Schaik; Isaac A Mizrahi
Journal:  J Urol       Date:  2011-03-17       Impact factor: 7.450

6.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

Authors:  R B Nadler; P A Humphrey; D S Smith; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

7.  Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Zhaoyong Feng; Sumit Isharwal; Patricia Landis; Debra J Elliot; Robert Veltri; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Bruce Trock; Lori J Sokoll
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

8.  Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy.

Authors:  Giovanni Lughezzani; Massimo Lazzeri; Alessandro Larcher; Giuliana Lista; Vincenzo Scattoni; Andrea Cestari; Nicoló Maria Buffi; Vittorio Bini; Giorgio Guazzoni
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

9.  Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Authors:  Massimo Lazzeri; Alexander Haese; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Vincenzo Scattoni; Vittorio Bini; Massimo Freschi; Amy Sussman; Bijan Ghaleh; Philippe Le Corvoisier; Josep Alberola Bou; Salvador Esquena Fernández; Markus Graefen; Giorgio Guazzoni
Journal:  Eur Urol       Date:  2013-01-24       Impact factor: 20.096

10.  The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.

Authors:  Hiromi Hirama; Mikio Sugimoto; Kazuto Ito; Taizo Shiraishi; Yoshiyuki Kakehi
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-19       Impact factor: 4.553
View more
  14 in total

Review 1.  A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.

Authors:  Brian T Helfand; Carly A Conran; Jianfeng Xu; William J Catalona
Journal:  Curr Opin Urol       Date:  2017-09       Impact factor: 2.309

Review 2.  Grade Migration of Prostate Cancer in the United States During the Last Decade.

Authors:  Leonardo D Borregales; Gina DeMeo; Xiangmei Gu; Emily Cheng; Vanessa Dudley; Edward M Schaeffer; Himanshu Nagar; Sigrid Carlsson; Andrew Vickers; Jim C Hu
Journal:  J Natl Cancer Inst       Date:  2022-07-11       Impact factor: 11.816

3.  The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.

Authors:  V J Gnanapragasam; K Burling; A George; S Stearn; A Warren; T Barrett; B Koo; F A Gallagher; A Doble; C Kastner; R A Parker
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

Review 4.  Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers.

Authors:  Wei Jin; Xiang Fei; Xia Wang; Yan Song; Fangjie Chen
Journal:  Mediators Inflamm       Date:  2020-05-04       Impact factor: 4.711

5.  The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy.

Authors:  Olga Dolejsova; Radek Kucera; Radka Fuchsova; Ondrej Topolcan; Hana Svobodova; Ondrej Hes; Viktor Eret; Ladislav Pecen; Milan Hora
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 6.  Diagnosis of prostate cancer.

Authors:  Jean-Luc Descotes
Journal:  Asian J Urol       Date:  2019-02-14

7.  Development of a Single Stranded DNA Aptamer as a Molecular Probe for LNCap Cells Using Cell-SELEX.

Authors:  Faezeh Almasi; Seyed Latif Mousavi Gargari; Fatemeh Bitaraf; Samaneh Rasoulinejad
Journal:  Avicenna J Med Biotechnol       Date:  2016 Jul-Sep

Review 8.  Role of mpMRI of the prostate in screening for prostate cancer.

Authors:  Christopher J D Wallis; Masoom A Haider; Robert K Nam
Journal:  Transl Androl Urol       Date:  2017-06

9.  Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.

Authors:  Enrique Gómez-Gómez; Juan M Jiménez-Vacas; Julia Carrasco-Valiente; Vicente Herrero-Aguayo; Ana M Blanca-Pedregosa; Antonio J León-González; José Valero-Rosa; José L Fernández-Rueda; Teresa González-Serrano; José López-Miranda; Manuel D Gahete; Justo P Castaño; María J Requena-Tapia; Raúl M Luque
Journal:  J Cell Mol Med       Date:  2018-09-06       Impact factor: 5.310

10.  Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.

Authors:  Stacy Loeb
Journal:  Urol Pract       Date:  2016-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.